Physician profile
Linda C White
NPI 1174975387
$12,519.07
in general payments reported to CMS, 2019-2025
25 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,366 · 2022: $1,760 · 2023: $2,553 · 2024: $2,835 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,334 · Education: $59.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,333.72 |
| Education | $59.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,942.49 | 2021-2025 | Dovato, Cabenuva, Rukobia |
| Gilead Sciences, INC. | $1,894.56 | 2021-2025 | Biktarvy, Veklury |
| Abbvie INC. | $1,080.17 | 2021-2025 | |
| Melinta Therapeutics, LLC | $1,054.99 | 2022-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Paratek Pharmaceuticals, INC. | $897.66 | 2021-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $648.46 | 2021-2025 | Pifeltro, Zerbaxa, Dificid |
| Shionogi INC | $379.63 | 2021-2025 | Fetroja |
| Insmed, INC. | $254.26 | 2021-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $251.71 | 2021-2023 | Symtuza |
| Janssen Products, Lp | $214.43 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $159.86 | 2022-2023 | Vibativ |
| Theratechnologies INC. | $159.68 | 2022-2024 | Egrifta, Trogarzo |
| Lilly USA, LLC | $148.79 | 2021-2025 | Zepbound, Emgality, Reyvow |
| Electromed, INC. | $68.47 | 2024-2025 | Smartvest |
| Mylan Specialty L.P. | $65.46 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $54.18 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Aimmune Therapeutics, INC. | $37.56 | 2024-2025 | Vowst |
| Mayne Pharma Commercial LLC | $33.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $32.96 | 2022 | |
| La Jolla Pharmaceutical Company | $29.34 | 2023 | Xerava |
| Astellas Pharma US INC | $27.67 | 2021 | |
| Organogenesis INC. | $27.36 | 2025 | Via Matrix |
| Smith+Nephew, INC. | $26.59 | 2021 | |
| Boston Scientific Corporation | $15.17 | 2021 | |
| Nabriva Therapeutics, Plc | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.